investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Delineating Heterogeneous Structural Complexity in Cancer Genomes

Ken Chen

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)
Next-generation sequencing (NGS) is enabling the routine, systematic analysis of somatic aberrations that accumulate in cancer genomes. Many of the functional mutations are structural, involving the deletion, duplication, translocation, insertion, or inversion of nucleotide sequences. Detecting these structural variations is fundamentally challenging due to the enormous number of ways a cancer genome can be altered and the presence of widespread repeats that obstruct the accurate alignment of short reads. Moreover, structural complexities are often compounded by clonal heterogeneity, i.e., mixtures of cell populations that contain heterogeneous aberrations in a tumor specimen, which result in diverse structural and copy number profiles. These issues pose an unprecedented challenge to developing practically useful computational tools that can be used to identify the presence of a structural variant and elucidate its functional and clinical relevance. To fully harness the power of NGS and to facilitate advances toward personalized medicine, we propose to develop a set of novel computational tools for detecting structural variants in heterogeneous cancer genomes. Specifically, we plan to pursue the following aims: 1) Develop novel computational tools for sensitive breakpoint detection and assembly, 2) Develop a statistical framework to characterize structural variants in heterogeneous tumors, and 3) Examine our tools through large-scale experimental validation and distribute the tools through an open source. Our short-term goal is to boost the transformation of the staggering amount of polyclonal NGS data produced by cancer genome sequencing projects such as The Cancer Genome Atlas and by the International Cancer Genome Consortium, to improve our understanding of tumor evolution and identify variants of functional and clinical relevance. Our long-term goal is to develop algorithms and prototypes that are usable in clinical settings for personalized diagnosis and treatment.

Related projects